TY - JOUR
T1 - Resumen ejecutivo
T2 - Enfermedad por hígado graso no alcohólico en sujetos con diabetes mellitus tipo 2: Postura conjunta de la Asociación Chilena de Hepatología (ACHHEP) y la Sociedad Chilena de Diabetología (SOCHIDIAB)
AU - Arab, Juan Pablo
AU - Castro, Lorena
AU - Gómez, Patricia C.
AU - Vignolo, Paulina
AU - Arrese, Marco
AU - Barrera, Francisco
AU - Castro, Fabiola
AU - Díaz, Luis Antonio
AU - Donoso, Anibal
AU - Elgueta, Karina
AU - González, Katherine
AU - González, María Isabel
AU - Moreno, Manuel
AU - Lazarte, Raúl
AU - Poniachik, Jaime
AU - Salman, Patricio
AU - Valderas, Juan Patricio
N1 - Publisher Copyright:
© 2021 Sociedad Medica de Santiago. All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - Non-alcoholic fatty liver disease (NAFLD) has a high prevalence and risk of progression to cirrhosis and other complications in patients with type 2 diabetes mellitus (T2DM). Likewise, the presence of NAFLD implies a high risk of developing T2DM, determining a bidirectional relationship between them. The diabetology and hepatology societies, developed a joint initiative aiming to unify criteria, reviewing the definitions, diagnostic criteria, risk stratification, treatment, and follow-up of patients with NAFLD and T2DM. The key questions to be discussed were defined by a panel of specialists in diabetology and hepatology. The Delphi methodology was used to reach consensus on the respective recommendations. Based on the discussion generated among the experts, diagnostic and treatment algorithms were proposed, as well as an indication for referral and the role of the different specialists involved in the management of these patients. Strengthening multidisciplinary work with patients with NAFLD and T2DM will allow the early recognition of the disease, the prevention of the progression to cirrhosis, and reducing the associated complications.
AB - Non-alcoholic fatty liver disease (NAFLD) has a high prevalence and risk of progression to cirrhosis and other complications in patients with type 2 diabetes mellitus (T2DM). Likewise, the presence of NAFLD implies a high risk of developing T2DM, determining a bidirectional relationship between them. The diabetology and hepatology societies, developed a joint initiative aiming to unify criteria, reviewing the definitions, diagnostic criteria, risk stratification, treatment, and follow-up of patients with NAFLD and T2DM. The key questions to be discussed were defined by a panel of specialists in diabetology and hepatology. The Delphi methodology was used to reach consensus on the respective recommendations. Based on the discussion generated among the experts, diagnostic and treatment algorithms were proposed, as well as an indication for referral and the role of the different specialists involved in the management of these patients. Strengthening multidisciplinary work with patients with NAFLD and T2DM will allow the early recognition of the disease, the prevention of the progression to cirrhosis, and reducing the associated complications.
KW - Diabetes Mellitus, Type 2
KW - Fatty Liver
KW - Liver Cirrhosis
KW - Non-alcoholic Fatty Liver Disease
UR - https://www.scopus.com/pages/publications/85126854926
U2 - 10.4067/S0034-98872021000901360
DO - 10.4067/S0034-98872021000901360
M3 - Article
C2 - 35319691
AN - SCOPUS:85126854926
SN - 0034-9887
VL - 149
SP - 1360
EP - 1371
JO - Revista Medica de Chile
JF - Revista Medica de Chile
IS - 9
ER -